Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Societe Generale Asset Management Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
SGAM AI is a leading institutional player in Alternative Investment Management. SGAM AI successfully mixes the cultures of asset management and capital markets. They are client driven and institutional, like an asset manager. Their approach of each market is entrepreneurial and financial, like an investment bank. They offer the widest coverage of Alternative Investment classes. Their size and profitability allow long term investments and credibility. They have the ability to offer solutions, not only products. SG Group&s;s strengths are brought to the Alternative Investment&s;s industry. They benefit from SG Group&s;s long term commitment in Alternative Investments. They use the processes ans resources of SGAM Group (rated M2 by Fitch).
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2005 | Genomic Vision | Series A | 2.4M |
| 11/2009 | Force-A | Series B | 2.1M |
| 7/2007 | Diatos | Series D | 12.8M |
| 1/2001 | Netasq | Series A | 1.6M |
| 7/2001 | Ornis | Venture Round | 4.4M |
| 11/2007 | Arterial Remodeling Technologies | Venture Round | 8M |
| 2/2003 | Cariocas | Series B | 5.3M |
| 11/2005 | IntegraGen | Series B | 9.4M |
| 4/2008 | Jobpartners | Series C | 0 |
| 1/2006 | Ariane Systems | Venture Round | 3.1M |
| 5/2006 | NEMOPTIC | Series D | 0 |
| 4/2005 | Biosystems International | Seed Round | 3.9M |
| 2/2006 | Cytomics Pharmaceuticals | Series B | 11.9M |
| 10/2006 | Infront Analytics | Series C | 2.8M |
| 6/2006 | Chronicle Solutions | Series A | 5.5M |
| 7/2008 | Genomic Vision | Series B | 6.3M |
| 8/2006 | Augure | Series C | 5.8M |
| 8/2000 | MEDoctor | Seed Round | 0 |
| 6/2000 | MakeMusic, Inc. | Series C | 0 |
| 11/2002 | BioForce Nanosciences | Venture Round | 2M |
| 5/2008 | Genkyotex | Series A | 4M |
| 12/2003 | DiBcom | Venture Round | 0 |
| 3/2003 | CellZome | Series C | 32M |
| 9/2007 | GQ Life Sciences | Series B | 0 |
| 1/2001 | DiBcom | Series A | 2.3M |
| 12/2003 | Ornis | Venture Round | - |
| 6/2005 | DiBcom | Series D | 0 |
| 10/1999 | Drug Abuse Sciences | Venture Round | 22.4M |
| 9/2008 | Augure | Series D | 11.3M |
| 1/2006 | DxO Labs | Series A | 12.8M |
| 2/2005 | Sequans Communications | Series B | 9.3M |
| 10/2006 | Open-Plug | Series B | 15M |
| 10/2007 | Ekinops | Series B | 20M |
| 9/2005 | Univa | Venture Round | 15M |
| 7/2007 | DiBcom | Series E | 0 |
| 1/2002 | Netasq | Series B | 3.6M |
| 10/2006 | Sequans Communications | Series C | 24M |
| 2/2005 | Augure | Series B | 1.6M |
| 1/2008 | Adocia | Venture Round | 17.4M |
| 3/2007 | Force-A | Series A | 3M |
| 1/2004 | DiBcom | Series C | 0 |
| 7/2004 | Netasq | Series C | 4.1M |
| 3/2002 | DiBcom | Series B | 2.6M |
| 1/2004 | Cyclacel Pharmaceuticals | Series D | 38.7M |
| 3/2001 | Drug Abuse Sciences | Series A | 46.5M |
| 12/2002 | Catalyst Bioscience | Venture Round | 46M |
| 11/2009 | Force-A | Series B | 0 |
| 9/2008 | Augure | Series D | 0 |
| 7/2008 | Genomic Vision | Series B | 0 |
| 5/2008 | Genkyotex | Series A | 0 |
| 4/2008 | Jobpartners | Series C | 0 |
| 1/2008 | Adocia | Venture Round | 0 |
| 11/2007 | Arterial Remodeling Technologies | Venture Round | 0 |
| 10/2007 | Ekinops | Series B | 0 |
| 9/2007 | GQ Life Sciences | Series B | 0 |
| 7/2007 | DiBcom | Series E | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
